The cost of Soliris can vary based on several factors, including your insurance coverage. Drug savings programs can also lower the price you’ll pay for Soliris. Soliris may need to be purchased ...

The price you pay for Soliris may depend on factors such as whether you have health insurance. Financial assistance may be available to help you with the cost of Soliris. your treatment plan your ...

(Reuters) - Apellis Pharmaceuticals Inc said on Tuesday its experimental drug for a blood disorder showed greater improvement in patients' hemoglobin levels than market leader Alexion Pharmaceuticals ...

AstraZeneca has been successful at rolling out its long-acting complement C5 inhibitor Ultomiris in the uses approved for its predecessor Soliris – until now, that is. The drugmaker confirmed this ...

FDA Approves Expanded Use of Eculizumab (Soliris) for Pediatric Myasthenia Gravis · GlobeNewswire Inc. New York, March 10, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) welcomes ...

In the PREVENT study, the safety and efficacy of Soliris was compared to placebo in patients with AQP4 auto antibody-positive NMOSD (N=143). Treatment with Soliris (eculizumab; Alexion) was associated ...

It took longer than some industry watchers expected, but Alexion has another indication for lead med Soliris in the bag. On Monday, the company said the FDA had greenlighted the product to treat ...

The FDA granted Alexion Pharmaceuticals’ (ALXN) Soliris orphan drug designation for treating patients suffering from myasthenia gravis (MG), a rare autoimmune deficiency which leads to the failure of ...

In its push to backstop sales of blockbuster Soliris, Alexion has touted its better-than-expected success at switching patients to follow-up drug Ultomiris. But if switching to the newer med is going ...

Alexion’s new drug for a rare blood disease has hit the mark in two Phase 3 clinical studies - just days after it emerged that EU regulators may overturn a patent on its rare diseases blockbuster ...

The FDA approved a fourth indication for Alexion Pharmaceuticals’ brand-name eculizumab (Soliris) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are ...

- 98% of adult anti-aquaporin-4 (AQP4) antibody-positive patients treated with SOLIRIS were relapse free compared to 63% receiving placebo at 48 weeks - “We are pleased that the Japanese health ...